TNFRSF4 and chronic myelogenous leukemia, BCR-ABL1 positive: Consequently, the efficacy of an agonistic TNFRSF4 antibody to modulate T cell immunity and to eliminate LSCs in CML patients could be directly addressed in patients who did not obtain a deep molecular remission, as well as in patients who relapsed after discontinuation of TKI therapy.